BioCentury | Aug 12, 2019
Financial News

AstronauTx launches to target astrocytes for Alzheimer's

...discovered at the Alzheimer's Research UK UCL Drug Discovery Institute (DDI). Reynolds said researchers at DDI...
BioCentury | May 3, 2019
Clinical News

GT Biopharma leveraging NK cells to treat HIV

...partner suggesting the company's TriKE modality could move the needle from life-long therapies to cures. GT Biopharma Inc....
...may only need to take medication until all latent cells are eliminated. The TriKE that GT Biopharma...
...developed includes an IL-15 linker. The cytokine helps NK cells activate and proliferate. Until now, GT Biopharma’s...
BioCentury | May 1, 2018
Distillery Therapeutics

Neurology

...in Phase III testing for mucositis and Phase II testing for head and neck cancer. GT Biopharma Inc....
BioCentury | Dec 13, 2017
Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Pompe's disease Mouse studies suggest gene therapies delivering secretion-optimized GAA variants could help treat Pompe’s disease. The gene therapies consist of a liver-tropic adeno-associated viral serotype 8 (AAV8) vector encoding one of two GAA...
BioCentury | Nov 14, 2017
Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Pompe's disease Mouse studies suggest GAA-loaded nanoparticles could help treat Pompe’s disease without generating anti-GAA antibodies associated with resistance to enzyme replacement therapy. The nanoparticles consist of low-immunogenic anionic phosphatidylinositol liposomes loaded with GAA....
BioCentury | Oct 6, 2017
Clinical News

Mateon discontinuing Zybrestat on Phase II/III ovarian cancer data

Mateon Therapeutics Inc. (OTCQX:MATN) discontinued development of Zybrestat fosbretabulin (combretastatin A4P, CA4P) after data from the first 70 platinum-resistant ovarian cancer patients enrolled in the Phase II/III FOCUS trial showed Zybrestat in combination with physician’s...
BioCentury | Feb 24, 2017
Clinical News

GBT440: Ph I Basecamp (GBT440-011) started

Global Blood Therapeutics began the open-label, U.S. Phase I Basecamp (GBT440-011) trial to evaluate 900 mg oral GBT440 once daily for 14 days in 12 healthy volunteers. Global Blood Therapeutics Inc. (NASDAQ:GBT), South San Francisco,...
BioCentury | Sep 5, 2016
Financial News

Oxis proposes private placement of units

...Oxis International Inc. (OTCQB:OXIS; Euronext:OXI), Beverly Hills, Calif. Business: Nutraceuticals, Cancer Date announced: 2016-08-24 Type: Private...
BioCentury | Jan 26, 2016
Clinical News

Relypsa gains on DDI data

...and CEO John Orwin said on a conference call that Relypsa was "hopeful" that the DDI...
...shorten the dose separation to three hours, or add language to the label addressing the DDI...
BioCentury | Nov 2, 2015
Clinical News

OXi4503 combretastatin A1 di-phosphate: Phase Ib/II started

OxiGene began an open-label, U.S. Phase Ib/II trial to evaluate OXi4503 as a single agent and in combination with intermediate-dose cytarabine. The dose-escalation Phase Ib portion will enroll up to 27 patients and the Phase...
Items per page:
1 - 10 of 202
BioCentury | Aug 12, 2019
Financial News

AstronauTx launches to target astrocytes for Alzheimer's

...discovered at the Alzheimer's Research UK UCL Drug Discovery Institute (DDI). Reynolds said researchers at DDI...
BioCentury | May 3, 2019
Clinical News

GT Biopharma leveraging NK cells to treat HIV

...partner suggesting the company's TriKE modality could move the needle from life-long therapies to cures. GT Biopharma Inc....
...may only need to take medication until all latent cells are eliminated. The TriKE that GT Biopharma...
...developed includes an IL-15 linker. The cytokine helps NK cells activate and proliferate. Until now, GT Biopharma’s...
BioCentury | May 1, 2018
Distillery Therapeutics

Neurology

...in Phase III testing for mucositis and Phase II testing for head and neck cancer. GT Biopharma Inc....
BioCentury | Dec 13, 2017
Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Pompe's disease Mouse studies suggest gene therapies delivering secretion-optimized GAA variants could help treat Pompe’s disease. The gene therapies consist of a liver-tropic adeno-associated viral serotype 8 (AAV8) vector encoding one of two GAA...
BioCentury | Nov 14, 2017
Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Pompe's disease Mouse studies suggest GAA-loaded nanoparticles could help treat Pompe’s disease without generating anti-GAA antibodies associated with resistance to enzyme replacement therapy. The nanoparticles consist of low-immunogenic anionic phosphatidylinositol liposomes loaded with GAA....
BioCentury | Oct 6, 2017
Clinical News

Mateon discontinuing Zybrestat on Phase II/III ovarian cancer data

Mateon Therapeutics Inc. (OTCQX:MATN) discontinued development of Zybrestat fosbretabulin (combretastatin A4P, CA4P) after data from the first 70 platinum-resistant ovarian cancer patients enrolled in the Phase II/III FOCUS trial showed Zybrestat in combination with physician’s...
BioCentury | Feb 24, 2017
Clinical News

GBT440: Ph I Basecamp (GBT440-011) started

Global Blood Therapeutics began the open-label, U.S. Phase I Basecamp (GBT440-011) trial to evaluate 900 mg oral GBT440 once daily for 14 days in 12 healthy volunteers. Global Blood Therapeutics Inc. (NASDAQ:GBT), South San Francisco,...
BioCentury | Sep 5, 2016
Financial News

Oxis proposes private placement of units

...Oxis International Inc. (OTCQB:OXIS; Euronext:OXI), Beverly Hills, Calif. Business: Nutraceuticals, Cancer Date announced: 2016-08-24 Type: Private...
BioCentury | Jan 26, 2016
Clinical News

Relypsa gains on DDI data

...and CEO John Orwin said on a conference call that Relypsa was "hopeful" that the DDI...
...shorten the dose separation to three hours, or add language to the label addressing the DDI...
BioCentury | Nov 2, 2015
Clinical News

OXi4503 combretastatin A1 di-phosphate: Phase Ib/II started

OxiGene began an open-label, U.S. Phase Ib/II trial to evaluate OXi4503 as a single agent and in combination with intermediate-dose cytarabine. The dose-escalation Phase Ib portion will enroll up to 27 patients and the Phase...
Items per page:
1 - 10 of 202